Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review

Javier Morales,Biff F Palmer,Biff F. Palmer

DOI: https://doi.org/10.1080/00325481.2024.2316572

2024-02-17

Postgraduate Medicine

Abstract:Chronic kidney disease (CKD) is a prevalent complication of Type II diabetes (T2D). The coexistence of CKD with T2D is comparable to cardiovascular disease (CVD) when the estimated glomerular filtration rate declines below 60 ml/min/1.73 m 2 . Screening and early detection of people with high risk for CKD would be beneficial in managing CKD progress and the associated complications such as CV complications. Renin-angiotensin-aldosterone system inhibitors (RAASi) have demonstrated beneficial effects in delaying CKD progression, but they carry the risk of hyperkalemia. Nonsteroidal mineralocorticoid antagonists (nsMRA), such as finerenone, exhibit considerable efficacy in their anti-inflammatory, antifibrotic, and renal protective effects with demonstrable reductions in CV complications. In addition, nsMRAs do not cause significant changes in serum potassium levels compared to traditional steroidal MRA. Ongoing research explores the capacity of the sodium-glucose transport protein 2 inhibitors (SGLT-2i), combined with nsMRA, to produce synergistic renal protective effects and reduce the risk of hyperkalemia. Also, a dedicated renal outcomes study (FLOW study) involving a once-weekly injectable Glucagon-like peptide-1 receptor agonist, semaglutide, was halted early by the data monitoring committee due to having achieved the predefined efficacy endpoint and considerations related to renal disease. In CKD patients with T2D on nsMRA, hyperkalemia management requires a comprehensive approach involving lifestyle adjustments, dietary modifications, regular serum potassium level monitoring, and potassium binders, if necessary. Withholding or down-titration of nsMRAs with close monitoring of serum potassium levels may be required in patients with concerning potassium levels. In light of the current state of knowledge, this review article explores the perspectives and approaches that HCPs may consider when monitoring and managing hyperkalemia in CKD patients with T2D. Chronic Kidney Disease (CKD) is a common and serious problem among people with Type II Diabetes (T2D). People who have CKD with T2D are at a higher risk for heart disease after normal kidney function declines below certain levels. Renin-angiotensin-aldosterone system inhibitors are a group of medications that can help delay CKD progression but may cause a rise in circulating potassium levels. Nonsteroidal mineralocorticoid antagonist (nsMRA), such as finerenone, can reduce kidney inflammation and damage, with noted cardiovascular benefits, and with less effect on serum potassium levels as compared to their steroid-based counterparts. Researchers are studying whether combining blood sugar medications such as sodium-glucose transport protein-2 inhibitors (SGLT-2i) and finerenone can help protect the kidneys and heart. They also want to see if this combination can prevent high potassium levels. This article talks about ways to check and monitor potassium levels in CKD patients with T2D who may be taking nsMRA. To manage high potassium levels in people with CKD and T2D, doctors may suggest lifestyle changes, dietary adjustments, potassium-lowering medication, or adjustment of other medications with close monitoring of potassium levels.

medicine, general & internal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is how to monitor and manage hyperkalemia when non - steroidal mineralocorticoid receptor antagonists (nsMRA) are used to treat patients with chronic kidney disease (CKD) combined with type 2 diabetes (T2D). Specifically, the paper explores the following aspects:

1. **Background and Importance**:
- Chronic kidney disease (CKD) is a common and serious complication of type 2 diabetes (T2D), affecting about one - third of adult diabetic patients.
- When the estimated glomerular filtration rate (eGFR) is lower than 60 ml/min/1.73 m², the co - existence of CKD and T2D is equivalent to the risk of cardiovascular disease (CVD).
- Renin - angiotensin - aldosterone system inhibitors (RAASi) have shown beneficial effects in delaying the progression of CKD, but these drugs may cause hyperkalemia.

2. **The Role of Non - steroidal Mineralocorticoid Receptor Antagonists (nsMRA)**:
- nsMRA such as finerenone has shown significant effects in anti - inflammation, anti - fibrosis and kidney protection, and can reduce cardiovascular complications.
- Compared with traditional steroidal mineralocorticoid receptor antagonists (sMRA), nsMRA has less impact on serum potassium levels.

3. **Monitoring and Management of Hyperkalemia**:
- The paper discusses in detail how to monitor and manage hyperkalemia when using nsMRA in patients with CKD combined with T2D.
- Monitoring methods include regular detection of serum potassium levels, electrocardiogram (EKG) examination and clinical evaluation.
- Management measures include lifestyle adjustment, diet modification, regular monitoring of serum potassium levels and the use of potassium binders (such as patiromer or sodium zirconium cyclosilicate) when necessary.

4. **Comprehensive Treatment Strategies**:
- The paper also explores the potential benefits of the combined use of nsMRA and other drugs (such as sodium - glucose cotransporter 2 inhibitor SGLT - 2i) to produce synergistic kidney protection effects and reduce the risk of hyperkalemia.

In conclusion, this paper aims to provide guidance for healthcare professionals to help them more effectively monitor and manage hyperkalemia when using nsMRA to treat patients with CKD combined with T2D, thereby optimizing the treatment effect and safety of patients.